Stockreport

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

Neuropace, Inc.  (NPCE) 
PDF — Published 3-year Post-Approval Study results show 82% median seizure reduction in drug-resistant focal epilepsy —— American Academy of Neurology (AAN) presentation fea [Read more]